Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

UNCY

Unicycive Therapeutics Inc

May 03 • 10:35AM ET

1.12

Dollar change +0.00
Percentage change 0.45	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	28.10%	Shs Outstand	34.76M	Perf Week	9.22%
Market Cap	39.10M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.00%	Shs Float	24.99M	Perf Month	-22.95%
Income	-31.22M	PEG	-	EPS next Q	-0.15	Inst Own	41.81%	Short Float	1.53%	Perf Quarter	20.61%
Sales	0.68M	P/S	57.51	EPS this Y	63.59%	Inst Trans	-3.15%	Short Ratio	0.90	Perf Half Y	100.89%
Book/sh	-0.11	P/B	-	EPS next Y	43.35%	ROA	-359.15%	Short Interest	0.38M	Perf Year	-9.27%
Cash/sh	0.28	P/C	4.03	EPS next 5Y	-	ROE	-700.45%	52W Range	0.47 - 1.82	Perf YTD	29.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-77.09%	ROI	-	52W High	-38.28%	Beta	2.71
Dividend TTM	-	Quick Ratio	0.76	Sales past 5Y	-5.80%	Gross Margin	57.93%	52W Low	139.36%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	0.76	EPS Y/Y TTM	-34.38%	Oper. Margin	-3077.78%	RSI (14)	45.28	Volatility	12.47% 10.19%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-29.02%	Profit Margin	-4625.04%	Recom	1.00	Target Price	5.30
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	35.85%	Payout	-	Rel Volume	0.71	Prev Close	1.12
Sales Surprise	-	EPS Surprise	-19.40%	Sales Q/Q	-	Earnings	Mar 28 AMC	Avg Volume	425.95K	Price	1.12
SMA20	-3.54%	SMA50	-16.70%	SMA200	18.68%	Trades		Volume	68,262	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-04-24	Initiated	Piper Sandler	Overweight	$9

Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks) +18.45%
Apr-10-24 07:03AM	Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-28-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -5.48%
04:15PM	Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 07:03AM	Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress (GlobeNewswire)
07:03AM	Loading…
Mar-14-24 07:03AM	Unicycive Announces $50 Million Private Placement (GlobeNewswire)
Mar-13-24 07:03AM	Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference (GlobeNewswire)
Mar-07-24 04:12PM	Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Mar-04-24 07:03AM	Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients (GlobeNewswire) -6.88%
Feb-14-24 07:03AM	Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting (GlobeNewswire) +10.48%
Jan-29-24 07:03AM	Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference (GlobeNewswire) +7.43%
Jan-24-24 09:39AM	Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update (Zacks)
Jan-23-24 07:03AM	Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones (GlobeNewswire) +18.29%
Dec-18-23 07:03AM	Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire)
Nov-29-23 07:03AM	Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023 (GlobeNewswire) -5.37%
04:15PM	Loading…
Nov-14-23 04:15PM	Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-23-23 07:03AM	Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC) (GlobeNewswire) -7.91%
Sep-06-23 07:03AM	Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD (GlobeNewswire)
Aug-29-23 07:03AM	Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series (GlobeNewswire)
Aug-14-23 05:36PM	Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-23 04:30PM	CORRECTION FROM SOURCE: 60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE)
Jul-20-23 07:03AM	Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference (GlobeNewswire)
Jul-18-23 07:03AM	Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology (GlobeNewswire)
Jun-29-23 05:04PM	Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program (GlobeNewswire)
Jun-16-23 07:38AM	Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET (GlobeNewswire) -7.59%
Jun-09-23 09:00AM	Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report® (ACCESSWIRE) +12.90%
May-17-23 06:03AM	Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook (Simply Wall St.)
May-16-23 08:29AM	Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-23 07:00AM	Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress (GlobeNewswire)
07:00AM	Loading…
Mar-31-23 07:00AM	Unicycive Announces Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +11.70%
Mar-08-23 06:04AM	Shareholders have faith in Unicycive Therapeutics (NASDAQ:UNCY) as stock climbs 36% in past week, taking one-year gain to 99% (Simply Wall St.) +8.00%
Mar-07-23 09:00AM	The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury (News Direct) +20.97%
Mar-06-23 07:00AM	Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb (GlobeNewswire) +153.06%
Mar-03-23 09:15AM	The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers (News Direct)
Feb-27-23 07:00AM	Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings (GlobeNewswire)
Feb-17-23 10:35AM	Unicycive: The Company Developing Key Kidney Therapies (News Direct)
Feb-06-23 09:59AM	Unicycive: This Biotech Company Receives Promising Results From New Trial (News Direct)
Feb-02-23 08:30AM	Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea (GlobeNewswire) -7.05%
Jan-23-23 07:00AM	Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundations Spring Clinical Meetings (GlobeNewswire) +5.34%
Jan-05-23 07:00AM	Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023 (GlobeNewswire) -8.98%
Dec-29-22 11:31AM	Unicycive Announces Termination of At-The-Market Offering of Shares of Common Stock (GlobeNewswire) +12.00%
Dec-28-22 09:21AM	Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study (Benzinga) -25.37%
08:30AM	Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb (GlobeNewswire)
Dec-22-22 07:00AM	Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (GlobeNewswire)
Dec-09-22 08:00AM	Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) (ACCESSWIRE)
Nov-28-22 07:00AM	Unicycive to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-21-22 10:32AM	Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies (Benzinga)
07:00AM	Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy (GlobeNewswire)
Nov-14-22 07:00AM	Unicycive Announces Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.59%
Nov-10-22 07:00AM	Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis (GlobeNewswire) +9.70%
Nov-08-22 09:00AM	Unicycives Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden (News Direct)
Oct-26-22 08:04AM	Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Oct-12-22 08:00AM	Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells (News Direct)
Sep-29-22 07:00AM	Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference (GlobeNewswire)
Sep-23-22 09:11AM	How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication (News Direct) -5.33%
Sep-07-22 07:00AM	Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI) (GlobeNewswire) +6.59%
Sep-06-22 07:00AM	Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +5.80%
Aug-24-22 07:00AM	Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrologys Kidney Week 2022 (GlobeNewswire)
Aug-15-22 06:03PM	Unicycive Announces Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
Jul-26-22 07:00AM	Unicycive Reports Key Findings from Independent Renal Dietitian Survey (GlobeNewswire) -6.93%
Jul-20-22 07:12AM	Unicycive Reports Key Findings from Market Research with Nephrologists (GlobeNewswire)
Jul-18-22 07:48AM	Unicycive Inks Licensing Pact For Its Kidney Disease Candidate In China (Benzinga) +9.84%
07:00AM	Unicycive Announces Exclusive License and Development Agreement with Lees Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets (GlobeNewswire)
Jun-29-22 12:00PM	CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases (Newsfile)
Jun-06-22 08:00AM	Unicycive to Present at JMP Securities Life Sciences Conference (GlobeNewswire) +11.90%
Jun-02-22 08:00AM	Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia (GlobeNewswire)
May-24-22 08:00AM	Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc. (ACCESSWIRE) +7.17%
May-12-22 07:00AM	Unicycive Announces First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Apr-14-22 07:10AM	Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney Diseases (GlobeNewswire) +5.88%
Mar-31-22 07:00AM	Unicycive Announces Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-22 08:30AM	Unicycive To Ring the Nasdaq Closing Bell on March 29, 2022 (GlobeNewswire)
Mar-03-22 07:00AM	Unicycive to Present at Upcoming March Investor Conferences (PR Newswire)
Feb-02-22 07:00AM	Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting (PR Newswire)
Jan-10-22 07:00AM	Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Nov-29-21 07:00AM	Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway (PR Newswire) -13.36%
Nov-11-21 09:14AM	Unicycive Therapeutics Announces Third Quarter 2021 Financial Results (PR Newswire)
Oct-26-21 07:30AM	Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy (PR Newswire) +9.09%
Sep-15-21 06:17AM	Unicycive Therapeutics to be Added to Russell Microcap® Index (PR Newswire)
Sep-07-21 06:00AM	Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-16-21 06:00AM	Unicycive Therapeutics Announces Second Quarter 2021 Financial Results (PR Newswire)

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UNCY

Unicycive Therapeutics Inc

Upgrade your FINVIZ experience